Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Osaka, Japan & Cambridge, Mass., United States:   HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the

READ MORE

SMT Launches Hydra™ TAVI System in Russia, Offering Advanced Care for Aortic Stenosis Patients

Sahajanand Medical Technologies Ltd. (SMT)   Mumbai, Maharashtra, India:  SMT (Sahajanand Medical Technologies), a global leader in innovative cardiovascular solutions, announces

READ MORE

HistoSonics Edison® Histotripsy System Treats First Pancreatic Tumor Patients in GANNON Trial

MINNEAPOLIS, United States:   HistoSonics, the developer and manufacturer of the Edison® Histotripsy System, announced today the first patients with pancreatic

READ MORE

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

Zug, Switzerland:   Ad hoc announcement pursuant to Art. 53 LR   Approximately 7% of people in the United States

READ MORE

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Osaka, Japan & Cambridge, Mass., United States:    Six Late-Stage Programs with Peak Revenue Potential of $10B – $20B1 Poised

READ MORE

‘Insults towards India’: Kolkata hospital says won’t treat Bangladeshi patients | India News

NEW DELHI: A hospital in Kolkata’s Manicktala area said that it will no longer treat Bangladeshi patients, citing protests over alleged atrocities against minority Hindus

READ MORE

HistoSonics® Enrolls First Patients in Company’s Novel BOOMBOX Master Study

MINNEAPOLIS, United States:   HistoSonics, the developer and manufacturer of the Edison® Histotripsy System, announced today the first patients were enrolled

READ MORE

Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial

Darmstadt, Germany:   Phase III MANEUVER study met primary endpoint, with an objective response rate at week 25 of 54.0%

READ MORE

Method for Scalp Cooling Now Offered to More Patients – Reduces Hair Loss in Cancer Patients

  The Aleris Oncology Clinic at Sabbatsberg Hospital, Stockholm – Sweden is expanding access to an innovative scalp cooling treatment

READ MORE

First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma

  Oslo, Norway, November 6, 2024 – Lytix Biopharma, a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer

READ MORE